Brossard, Quebec — September 3, 2025 — Leads & Copy — Diagnos Inc. has announced a non-brokered private placement of 10 units at $10,000 per unit, totaling $100,000 in gross proceeds. Each unit includes a $10,000 unsecured convertible debenture and 10,000 stock warrants. The debentures have a 12-month term with a 10% annual interest rate, convertible into common shares at $0.28 per share. Each warrant allows the holder to purchase one share at $0.40 per share during the term.
The funds will support product development, commercialization of AI-based screening services, and general administrative expenses. A director of the corporation will subscribe for all units in the private placement. All securities issued are subject to a 4-month statutory hold period. The placement awaits required approvals, including TSX Venture Exchange approval, receipt of funds, and formal documentation.
Diagnos Inc. specializes in early detection of critical eye-related health issues using AI to improve diagnostic accuracy and patient outcomes.
Mr. André Larente, President DIAGNOS Inc. Tel: 450-678-8882 ext. 224 alarente@diagnos.ca
Source: Diagnos Inc.
